Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients

AIDS

Volumn 12, Issue 18, 1998, Pages 2369-2375

  Birk, Markus ^a   Sönnerborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiretroviral therapy; HIV drug resistance; Protease inhibitors; Resistance mutations; Reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DRUG SENSITIVITY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURAL GENE; VIRUS TRANSMISSION;

EID: 0032564526     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199818000-00005     Document Type: Article

References (46)

1. Preston BD, Poiesz BJ, Loeb IA: Fidelity of HIV-1 reverse transcriptase. Science 1988, 242:1168-1171.
2. Peng C, Ho BK, Chang IW, Chang NI: Role of human immunodeficiency virus type 1 specific protease in core protein maturation and viral infectivity. J Virol 1989, 63:2550-2556.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
4. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
5. Birk M, Sönnerborg A, Vahlne A, Sällberg M: Non-synonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules. AIDS Res Hum Retroviruses 1998, 14:241-248.
6. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
7. Phillips RE, Rowland-Jones S, Nixon DE, et al.: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991, 354:453-459.
8. Craig C, Moyle G: The development of resistance of HIV-1 to zalcitabine [editorial]. AIDS 1997, 11:271-279.
9. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC: Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997, 41:757-762.
10. Iisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vivo selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
11. Deminie CA, Bechtold CM, Riccardi K, et al.: Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy [letter]. AIDS 1998, 12:110-112.
12. Tisdale M, Alnadaf I, Cousens D: Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997, 41:1094-1098.
13. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
14. Kellam P, Boucher CA, Larder BA: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992, 89:1934-1938.
15. Freimuth WW: Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcripta inhibitor. Adv Exp Med Biol 1996, 394:279-289.
16. Winslow DI, Garber S, Reid C, et al.: Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 1996, 10:1205-1209.
17. Demeter IM, Meehan PM, Morse G, et al.: HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Aquir Immune Defic Syndr Hum Retrovirol 1997, 14:136-144.
18. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666.
19. Eberle J, Bechowsky B, Rose, D, et al.: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses 1995, 11:671-676.
20. Roberts NA, Craig CJ, Sheldon J: Resistance and cross-resistance with saquinavir and other protease inhibitors: theory and practice. AIDS 1998, 12:453-460.
21. Roberts NA: Drug-resistance patterns of saquinavir and other proteinase inhibitors. AIDS 1995, 9 (suppl 2):S27-S32.
22. Patick AK, Mo H, Markowitz M, et al.: Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996, 40:292-297.
23. Schmit J-C, Ruiz L, Cloted B, et al.:Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996, 10:995-999.
24. Condra JH, Scleif WA, Blahy OM, et al.: In vivo emerge of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
25. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
26. Molla A, Korneyeva M, Gao Q. et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996, 2:760-766.
27. Partaledis JA, Yamaguchi K, Lisdale M, et al.: In vitro selection and characterization of human immunodeficiency virus type 1 isolates with reduced sensitivity to hydroxyethylamino sulfamide inhibitors of HIV-1 aspartyl protease. J Virol 1995, 69:5228-5235.
28. Doyon I , Corteau G, Thibeault D, Poulin F, Pilote L, Lamarre D: Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996, 70:3763-3769.
29. Zhang Y-M, Imamichi H, Imamichi T, et al.: Drug resistance during indinavir therapy is caused by mutations in the protease gene and its gag substrate cleaving sites. J Virol 1997, 71:6662-6670.
30. CAESAR Coordinating Committee: Randomised trial of addition of lamivudine or lamivudine plus lorivide to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
31. Feinberg M: Hidden dangers of incompletely supressive antiretroviral therapy. Lancet 1997, 349:1408-1409.
32. Finzi D, Hermankova M, Pierson I, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
33. Hecht FM, Grant RM, Petropoulos CJ, et al.: Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N Engl Med 1998, 339:307-311.
34. Mayers D: Rational approaches to resistance: nucleoside analogues. AIDS 1996, 10 (suppl 1):S9-S13.
35. Ribeiro RM, Bonhoeffer S, Nowak MA: The frequency of resistant mutant virus before antiviral therapy. AIDS 1998, 12:461-465.
36. Sönnerborg A, Johansson B, Ayehunie S, Julander I: Transmission of zidovudine-resistant human immunodeficiency virus [letter]. AIDS 1993, 7:1684-1685.
37. Erice A, Mayers D, Strike DG, et al.: Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:1163-1165.
38. Kozal M, Leahy N, Hanrahan J, Swack N, Stapleton J: Genotypic analysis of HIV-1 pol genes from drug-naive patients presenting to clinic between 1993-1998 and drug-experienced patients failing antiretoviral combination therapy with reverse transcriptase inhibitors and protease inhibitors. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 114].
39. Yerly S, Kaiser L, Race E, Clavl F, Perrin L: Reverse transcriptase and protease gene analysis at the time of primary HIV-1 infection, Second International Workshop on HIV Drug Resistance and treatment Strategies, Lake Maggiore, Italy, June 1998 [abstract 107].
40. Grant RM, Hecht FM, Petropoulos CJ, et al.: Transmission of HIV-1 resistant to multiple reverse transcriptase and protease inhibitors. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 108].
41. Riva C, Berlusconi A, Violin M, et al.: Prevalence of drug-resistant HIV-1 variants of RT region and natural polymorphism in protease coding region of recently infected individuals. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 117].
42. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-clade B protease gene using high-density oligonucleotid arrays. Nat Med 1996, 2:753-759.
43. Lech WJ, Wang G, Yang YL, et al.: In vivo diversity of the human immunodeficiency virus type 1: presence of protease inhibitor resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
44. Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, Goudsmit J: pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol 1997, 71:6348-6358.
45. Rose RE, Gong Y-F, Greytok JA, et al.: Human immunodeficiency virus type 1 background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996, 93:1648-1653.
46. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD: Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993, 365:671-673.